[Skip to Navigation]
Evidence to Practice
January 2018

Benefits, Limitations, and Value of Abuse-Deterrent Opioids

Author Affiliations
  • 1Harvard Health Publishing, Harvard Medical School, Boston, Massachusetts
  • 2Center for Health Policy and Law, Northeastern University School of Law, Boston, Massachusetts
  • 3Health Care Policy and Law Editor, JAMA Internal Medicine, Chicago, Illinois
  • 4Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts
  • 5Division of Global Public Health, Department of Medicine, University of California San Diego School of Medicine, La Jolla
  • 6Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2018;178(1):131-132. doi:10.1001/jamainternmed.2017.7259

The Institute for Clinical and Economic Review (ICER) issued a final evidence report,1 including a systematic literature review and cost-benefit analyses, to support a July 20, 2017, public meeting of the New England Comparative Effectiveness Public Advisory Council on abuse-deterrent (AD) opioids. We summarize key findings of the report and provide our independent assessment of their implications for health policy. While acknowledging the importance of reducing stigma in clinical discourse, we use the term abuse for consistency with the report nomenclature.

Add or change institution